Mefenamic Acid Market

The Mefenamic Acid market is projected to grow at a CAGR of 3.9% between 2025 and 2035, primarily fueled by its effectiveness in treating mild to moderate pain, including menstrual cramps and inflammation-related discomfort. A member of the anthranilic acid derivatives class of NSAIDs, Mefenamic Acid inhibits cyclooxygenase enzymes, making it effective for short-term pain relief. It is widely used in regions where alternatives like ibuprofen or naproxen are less dominant, especially for dysmenorrhea and muscle pain. The market also benefits from a steady demand for cost-effective, over-the-counter analgesics in developing economies, where prescription conversion into generic medications is increasing.

Geographically, Asia-Pacific dominates the Mefenamic Acid market, led by countries such as India, Indonesia, and the Philippines, where it remains a first-line treatment for menstrual pain and general analgesia. North America and Europe have more limited use, often due to preference for newer NSAIDs with improved gastrointestinal safety profiles. However, niche applications and continued use in specific formulations support stable demand. In Latin America and the Middle East & Africa, growing access to generics and increased awareness of women’s health are supporting market expansion, especially in retail and public health sectors.

The market report is evolving by holds a strong position in pain and inflammation management, particularly in emerging economies. Its established safety and efficacy in short-term use, particularly for dysmenorrhea, support steady global demand. Manufacturers focusing on affordable generics and broad distribution will continue to benefit, especially in retail pharmacy and public health channels.